

Agenda

1. 2019 US NOURIANZ™ (Istradefylline) Commercial Update

Len Paolillo

**Executive Vice President, Chief Commercial Officer
Kyowa Kirin, Inc.**

2. A Phase 2a study of KW-6356 in the Subjects with Parkinson's Disease

Mitsuo Satoh, Ph.D.

**Executive Officer
Vice President, Head of R&D Division**

3. Q&A